INTRODUCTION: With the advent of improved diagnostic and imaging techniques, it is now possible to detect renal cancers in their very early stages, when they are still present as small renal masses. In these situations, use of laparoscopic partial nephrectomy (LPN) techniques are indicated and have gained acceptance in major medical institutions worldwide, offering comparable oncological outcomes and improving quality of life in the patient when contrasted with open nephrectomy procedures. However, a complication that may occur during or after this surgery is the possibility of compromising renal function, as a result of extended ischemia times of more than 30 min. We have undertaken a systematic study of the potential of several agents that may enhance renal parenchymal preservation without causing unwanted renal dysfunction as a result of enhanced ischemia times. In this study, we have evaluated the potential of one such agent under study, namely hydralazine, which was shown earlier to enhance hypoxia inducible factor-1α (HIF-1α) levels in experimental animal systems. Our aim was to determine whether enhanced levels of HIF-1α via pre-treatment with hydralazine had a reno-protective effect after ischemic injury. MATERIALS AND METHODS: Rats were injected with hydralazine or saline for 5 days prior to right nephrectomy and 40 min of cross-clamping of the left renal pedicle. Ischemic damage was monitored via serum chemistry and renal pathology. RESULTS: In our system, we found that hydralazine pre-treatment, even though it enhanced HIF-1α levels in the kidney, it also increased serum creatinine and worsened the morphological damage to the renal tubules in the ischemic kidney. CONCLUSIONS: We conclude that even though this agent was described as a powerful inhibitor of prolyl hydroxylases, enhancing the levels of HIF-1α, it should be approached with caution when it is considered to enhance warm ischemia time and minimize the renal damage subsequent to LPN.
INTRODUCTION: With the advent of improved diagnostic and imaging techniques, it is now possible to detect renal cancers in their very early stages, when they are still present as small renal masses. In these situations, use of laparoscopic partial nephrectomy (LPN) techniques are indicated and have gained acceptance in major medical institutions worldwide, offering comparable oncological outcomes and improving quality of life in the patient when contrasted with open nephrectomy procedures. However, a complication that may occur during or after this surgery is the possibility of compromising renal function, as a result of extended ischemia times of more than 30 min. We have undertaken a systematic study of the potential of several agents that may enhance renal parenchymal preservation without causing unwanted renal dysfunction as a result of enhanced ischemia times. In this study, we have evaluated the potential of one such agent under study, namely hydralazine, which was shown earlier to enhance hypoxia inducible factor-1α (HIF-1α) levels in experimental animal systems. Our aim was to determine whether enhanced levels of HIF-1α via pre-treatment with hydralazine had a reno-protective effect after ischemic injury. MATERIALS AND METHODS:Rats were injected with hydralazine or saline for 5 days prior to right nephrectomy and 40 min of cross-clamping of the left renal pedicle. Ischemic damage was monitored via serum chemistry and renal pathology. RESULTS: In our system, we found that hydralazine pre-treatment, even though it enhanced HIF-1α levels in the kidney, it also increased serum creatinine and worsened the morphological damage to the renal tubules in the ischemic kidney. CONCLUSIONS: We conclude that even though this agent was described as a powerful inhibitor of prolyl hydroxylases, enhancing the levels of HIF-1α, it should be approached with caution when it is considered to enhance warm ischemia time and minimize the renal damage subsequent to LPN.
Authors: K K Meldrum; D R Meldrum; K L Hile; E B Yerkes; A Ayala; M P Cain; R C Rink; A J Casale; M A Kaefer Journal: Am J Physiol Cell Physiol Date: 2001-08 Impact factor: 4.249
Authors: P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe Journal: Science Date: 2001-04-05 Impact factor: 47.728
Authors: M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin Journal: Science Date: 2001-04-05 Impact factor: 47.728
Authors: Wanja M Bernhardt; Valentina Câmpean; Sarah Kany; Jan-Steffen Jürgensen; Alexander Weidemann; Christina Warnecke; Michael Arend; Stephen Klaus; Volkmar Günzler; Kerstin Amann; Carsten Willam; Michael S Wiesener; Kai-Uwe Eckardt Journal: J Am Soc Nephrol Date: 2006-06-08 Impact factor: 10.121
Authors: Natalya A Smirnova; Ilay Rakhman; Natalia Moroz; Manuela Basso; Jimmy Payappilly; Sergey Kazakov; Francisco Hernandez-Guzman; Irina N Gaisina; Alan P Kozikowski; Rajiv R Ratan; Irina G Gazaryan Journal: Chem Biol Date: 2010-04-23
Authors: Kenny Rao; Kapil Sethi; Joseph Ischia; Luke Gibson; Laurence Galea; Lin Xiao; Mildred Yim; Mike Chang; Nathan Papa; Damien Bolton; Arthur Shulkes; Graham S Baldwin; Oneel Patel Journal: PLoS One Date: 2017-07-07 Impact factor: 3.240